China-NZ CAR-T Deal Valued at USD 130m

China-NZ CAR-T Deal Valued at USD 130m

Summary

Wellington Zhaotai Therapies Limited (WZTL), the holding platform of China's Zhaotai, has signed a CAR-T cell therapy technology sublicence agreement with New Zealand's BioOra in Auckland, with a total contract value of USD 130 million. It is the first time Guangdong province has commercially licensed an independently developed tumour immunotherapy cell therapy product to a developed country. WZTL is 86.5 percent owned by China's Zhaotai and 13.5 percent by MBL, an entity under New Zealand's Malaghan Institute of Medical Research, and is the core delivery platform for nearly a decade of China-New Zealand biomedical research collaboration.

Under the agreement, the CAR-T therapy products will be jointly advanced through subsequent clinical development and commercialisation in agreed international markets outside Greater China and India. Tang Zhaoyang, chairman of China's Zhaotai and WZTL, said the USD 130 million deal is the result of nearly a decade of sustained investment by research teams from both countries. In 2016, China's Zhaotai began technical cooperation with the Malaghan Institute; in 2017, the two sides jointly established WZTL; in 2019, they signed a deepened cooperation agreement during the entrepreneurs' conference of the second Belt and Road Forum for International Cooperation, and launched New Zealand's first nationwide CAR-T clinical trial the same year; in 2023, at the Guangzhou event marking the 50th anniversary of China-New Zealand diplomatic relations, the project was highlighted by then New Zealand Ambassador to China, Grahame Morton.

Previously, in 2022, China's Zhaotai commercially licensed a CAR-T innovative drug for lymphoma to India's Dr Reddy's Laboratories; in 2024, China Customs approved its CAR-T cell products for entry into Hong Kong hospitals. Tang said the signing is a key step for independently innovative technology to go global through the China-New Zealand cooperation network, and that the company will continue to work with BioOra and more industry chain partners to advance subsequent clinical development and commercialisation of the therapy in agreed international markets, while creating more high-end medical industry jobs and commercial returns for New Zealand.

Commentary

The USD 130 million CAR-T technology sublicence agreement between China's Zhaotai and New Zealand's BioOra marks an important milestone in China-New Zealand biomedical cooperation, moving from joint research and development to commercialisation. As a frontier field in tumour immunotherapy, CAR-T therapies are expected to exceed USD 10 billion globally by 2027, but high costs and manufacturing complexity remain commercialisation bottlenecks. In this deal, the Malaghan Institute's participation through holding platform WZTL reflects New Zealand's strengths in clinical research and regulation, while China's Zhaotai provides independently owned intellectual property technology, creating complementarity.

For NZ SMEs, the cooperation could bring opportunities to participate in the cell therapy supply chain, such as cold chain logistics, biomanufacturing equipment and clinical trial services. New Zealand's biotechnology industry is small but high in research quality, and the deal is expected to attract more international capital to the local innovation ecosystem. At the same time, Chinese pharmaceutical companies have accelerated licence-out deals in recent years, with total upfront payments for outbound licensing exceeding USD 40 billion in 2023, showing growing international recognition of China's innovative drugs.

However, commercialisation of CAR-T therapies still faces challenges such as production standardisation and payment systems, and New Zealand companies need to assess their ability to enter specific segments. From a regional perspective, Guangdong, as a major Chinese biomedical hub, may offer New Zealand a new path for technology introduction and joint development through its companies' overseas expansion model.

Keywords: CAR-T cell therapy, technology sublicence, China's Zhaotai, New Zealand's BioOra, USD 130 million, China-New Zealand cooperation, Wellington Zhaotai Therapies, Malaghan Institute of Medical Research, Tang Zhaoyang, commercialisation licence


Source: Economic and Commercial Office of the Ministry of Commerce at the Chinese Consulate-General in Auckland

Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.